To highlight the advancements in biopharmaceutical manufacturing and drug discovery in 2025, focusing on in vivo CAR-T therapies and the industrialization of New Approach Methodologies (NAMs).
Key Findings:
In vivo CAR-T therapies shift manufacturing inside the human body, improving scalability and access.
The FDA Modernization Act 2.0 prompted a move away from unreliable animal models toward standardized NAMs.
Standardization in organoid science is essential to overcome the reproducibility crisis.
Interpretation:
The biopharmaceutical industry is moving towards a future of standardized, reproducible engineering, enhancing both therapy accessibility and drug discovery predictability.
Limitations:
The quality of starting materials and delivery mechanisms is critical for in vivo therapies.
Standardization efforts in NAMs are still in progress and may face challenges.
Conclusion:
2025 marked a pivotal year in biopharmaceuticals, demonstrating that while biology is complex, it can be managed through engineering principles, leading to more effective therapies and drug discovery processes.
